Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Acceleron Pharma revenue
Acceleron Pharma's revenue is $92.5 million.
What is Acceleron Pharma's revenue?
- Acceleron Pharma's revenue growth from 2014 to 2020 is 532.33%.
- Acceleron Pharma annual revenue for 2020 was 92.5M, 25.04% growth from 2019.
- Acceleron Pharma has 312 employees, and the revenue per employee ratio is $296,548.
- Acceleron Pharma's peak quarterly revenue was $39.8M in 2020(q2).
- Acceleron Pharma peak revenue was $92.5M in 2020.
- Acceleron Pharma annual revenue for 2019 was 74.0M, 428.86% growth from 2018.
On this page
Zippia finds jobs where you're a top candidate and applies on your behalf.
Acceleron Pharma historical revenue
Acceleron Pharma's peak revenue was $92.5M in 2020. The peak quarterly revenue was $39.8M in 2020(q2).
Acceleron Pharma's revenue increased from $14.6m in 2014 to $92.5M currently. That's a 532.33% change in annual revenue.
Acceleron Pharma annual revenue
Acceleron Pharma annual revenue over time
| Fiscal year / year | Acceleron Pharma revenue |
|---|---|
| 2014 | $14.6M |
| 2015 | $18.1M |
| 2016 | $27.8M |
| 2017 | $13.5M |
| 2018 | $14.0M |
| 2019 | $74.0M |
| 2020 | $92.5M |
Rate Acceleron Pharma's financial transparency
Acceleron Pharma annual growth
Acceleron Pharma saw the greatest revenue growth in 2019, when revenue increased by 428.86%.
Acceleron Pharma had the lowest revenue growth in 2017, when revenue changed by -51.46%.
Acceleron Pharma annual growth rate over time
| Year | Acceleron Pharma growth |
|---|---|
| 2015 | 24%↑ |
| 2016 | 53%↑ |
| 2017 | -51%↓ |
| 2018 | 4%↑ |
| 2019 | 429%↑ |
| 2020 | 25%↑ |
Acceleron Pharma quarterly revenue over time
- Q1
- Q2
- Q3
- Q4
Acceleron Pharma quarterly growth rate over time
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2014 | $3.3M | $4.1M | $3.5M | $3.7M |
| 2015 | $4.4M | $5.7M | $4.2M | $3.8M |
| 2016 | $18.2M | $3.2M | $3.0M | $3.4M |
| 2017 | $3.7M | $3.1M | $3.0M | $3.7M |
| 2018 | $3.2M | $3.7M | $3.3M | $3.8M |
| 2019 | $2.8M | $27.7M | $4.2M | $39.3M |
| 2020 | $4.3M | $39.8M | $22.6M | $25.9M |
| 2021 | $24.8M | $27.9M | $34.2M | - |
Acceleron Pharma jobs nearby
Do you work at Acceleron Pharma?
Is Acceleron Pharma transparent about its revenue structure?
Acceleron Pharma financial information
| CEO | Habib J. Dable |
| Company Type | Public |
| Employees Number | 312 |
| Date Founded | 2003 |
| Headquarters | Cambridge, Massachusetts |
| Number of Locations | 1 |
| Revenue | $92.5M |
| Net Income | -$166,030,000 |
| PE Ratio | -12.28 |
| Tax Rate | -0.0% |
| Market Capitalization | $2.0B |
| Total Assets | $932,337,000 |
| Ticker | XLRN |
Acceleron Pharma jobs you might like
Acceleron Pharma financing
Acceleron Pharma received early financing of $9.0M on 2004-02-17.
| Series | Round size | Date |
|---|---|---|
| Convertible Note | $9.0M | 02/2004 |
| Series A | $9M | 08/2004 |
| Debt Financing | $8M | 01/2006 |
| Series B | $30M | 08/2006 |
| Series C | $31M | 10/2007 |
| Series Unknown | $11.0M | 12/2009 |
| Series Unknown | $10.3M | 06/2010 |
| Grant | $1.5M | 01/2011 |
| Series D | $30M | 12/2011 |
| Post Ipo Equity | $10M | 09/2013 |
| Post Ipo Equity | $129M | 01/2014 |
| Post Ipo Equity | $215.8M | 09/2017 |
| Post Ipo Equity | $492.5M | 06/2020 |
Acceleron Pharma investors
| Investors | Security type |
|---|---|
| HERCULES CAPITAL INC | Debt Financing |
| Sutter Hill Ventures | Series B |
| Polaris Partners | Series B |
| Venrock | Series B |
| Advanced Technology Ventures | Series B |
| OrbiMed Advisors | Series B |
| Flagship Pioneering Inc | Series B |
| Sutter Hill Ventures | Series C |
| Polaris Partners | Series C |
| QVT Financial | Series C |
| Bessemer Venture Partners | Series C |
| MPM Capital | Series C |
| Venrock | Series C |
| Advanced Technology Ventures | Series C |
| OrbiMed Advisors | Series C |
| Flagship Pioneering Inc | Series C |
| Polaris Partners | Series Unknown |
| Venrock | Series Unknown |
| Advanced Technology Ventures | Series Unknown |
| OrbiMed Advisors | Series Unknown |
| Flagship Pioneering Inc | Series Unknown |
| CELGENE CORP DE | Series D |
Acceleron Pharma competitors
Acceleron Pharma's top competitor, Johnson & Johnson, earned an annual revenue of $88.8B.
Acceleron Pharma's smallest competitor is Metabolix with revenue of $9.1M last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Regeneron | $85,589 | $14.2B | 9,123 | 268 |
| Seagen | $85,008 | $2.0B | 900 | - |
| Exelixis | $108,978 | $2.2B | 484 | 174 |
| Moderna | $81,825 | $3.2B | 2,500 | 6 |
| Amgen | $93,349 | $33.4B | 22,000 | 537 |
| Gilead Sciences | $99,828 | $28.8B | 11,800 | 770 |
| Johnson & Johnson | $76,686 | $88.8B | 134,500 | 1,857 |
| Vertex Pharmaceuticals | $95,952 | $11.0B | 3,400 | 274 |
| Zoetis | $87,092 | $9.3B | 11,300 | 211 |
| Forest Laboratories | $91,901 | $3.6B | 6,200 | - |
Search for jobs
Related company revenues
Working at related companies
Related company jobs
Acceleron Pharma highest paying jobs
Zippia gives an in-depth look into the details of Acceleron Pharma, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Acceleron Pharma. The employee data is based on information from people who have self-reported their past or current employments at Acceleron Pharma. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Acceleron Pharma. The data presented on this page does not represent the view of Acceleron Pharma and its employees or that of Zippia.
Acceleron Pharma may also be known as or be related to ACCELERON PHARMA INC, Acceleron Pharma, Acceleron Pharma Inc, Acceleron Pharma Inc. and Acceleron Pharma, Inc.